.jpg?20250205')
Viridian Therapeutics said on Monday its experimental drug to treat chronic thyroid eye disease (TED) met the main goal of a late-stage study, sending the company's shares up more than 13% in premarket trading.
The drug, veligrotug, helped to significantly relieve symptoms of the immune system condition, the drug developer said.
TED causes inflammation and damage to the tissues around the eye and is estimated to affect between 90 and 300 per 100,000 people in the US.
The company plans to apply for US approval in the second half of 2025.
&uuid=(email))